Current Clinical Trials
Stem Cell Therapy for Cystinosis - UC San Diego
The Food and Drug Administration approved the first clinical trial for 6 adults with cystinosis using stem cell and gene therapy.
Location: UC San Diego, La Jolla, California
The phase I / II human clinical trials are being held at UC San Diego Health in San Diego, CA. The recruitment period has begun. Individuals must be 18 years or older and meet specific eligibility requirements to participate. The subsequent phases of the clinical trials may include children, however, timing and approvals of this have yet to be determined. The trials are available to individuals worldwide, though priority will be given to U.S. patients.
The following criteria must be met to participate in this study:
- Male or female who are 18 years and older of age.
- Diagnosed with cystinosis, i.e., early onset of Fanconi syndrome, and history of elevated white blood cell cystine level and/or history of or presence of cystine crystals in the eye.
- Must be at least one year post kidney transplant status.
- Must have adequate blood, thyroid, kidney and liver functions.
- Must be willing to use highly effective contraception whether male or female.
- Must be willing to comply with the study restrictions and requirements.
- Must be willing to discontinue cysteamine therapy (oral and/or eye drop) for various periods of time while in this study.
- Must have a family or friend caretaker available at all times during the study.
Additional information can be found by clicking here. If you are an adult with cystinosis and are interested in participating in the trial or would like more information please contact Anne Sawyers, email@example.com or phone: 858-246-4986
Does Cystinosis Affect Brain Function? New Study Seeks to Provide Answers
This CRF funded study is now recruiting patient volunteers. Dr. Sophie Molholm’s project aims to gain a better understanding of how brain function is affected by cystinosis, focusing on auditory and visual processing and memory. Contact Ana Francisco firstname.lastname@example.org or call (718) 862-1824 for more information.
Characterization of Distal Myopathy and Dysphagia in Nephropathic Cystinosis and Evaluation for Muscle Regenerative Capacity
NOW OPEN TO ADULTS 18+ YEARS
Dr. Reza Seyedsadjadi and Dr. Florian Eichler of the Massachusetts General Hospital (MGH) Center for Rare Neurological Diseases are conducting a study to learn more about muscle weakness and swallowing difficulties in Nephropathic Cystinosis and the ability of these muscles to regenerate (rebuild themselves). This study is currently funded by the Cystinosis Research Foundation (CRF).
For more information about the study click here.
Therapeutic Strategy for Cystinotic Nephropathy with iPS Cells, Dr. Benjamin “Beno” Freedman, PhD, University of Washington, Seattle, Washington
The goal of our CRF project is to use human mini-kidneys as surrogates for patients, to explore the potential of kidney regeneration, gene therapy, and drug discovery for cystinosis. We are seeking to recruit patients with cystinosis, and turn their urine into stem cells and kidney grafts, which we will test for transplantability. There is no obligation. Study participation is on a purely volunteer basis and is free of charge without compensation. If you are interested in joining the study or have questions about it, please contact Dr. Freedman for more information at email@example.com.
The Effect of Resistance Exercise on Muscle Dysfunction in Cystinosis
A CRF research study being conducted by Richard Reimer, MD, Associate Professor of Neurology, Stanford University School of Medicine, Palo Alto, California. If you are interested in participating in the study please contact Dr. Reimer at firstname.lastname@example.org for more details.
Phase 2 Study ELX- 02 in Patients with Nephropathic Cystinosis Montreal, Canada – POSTPONED
As many of you know, we launched the trial last fall and recruited the first small cohort to test a range of doses for effect on WBC cystine and safety. This first round identified the dosing threshold at which ELX-02 begins to reverse cystine accumulation and showed no auditory or renal side effects. The preliminary results from this study have shown clear biologic activity and are very exciting. However, due to study design limitations, this study has been stopped and a new design is being considered. Also, with the unexpected arrival of the COVID19 epidemic, most such clinical trials are suspended in North America.
In the interim, we will use the time to study our new CtnsW138X mouse model to ascertain whether early ELX-02 treatment can prevent Fanconi syndrome. I will keep the community updated from time to time on the CRF registry website.
For further information, please contact Dr. Paul Goodyer of McGill University Health Center in Montreal, Canada or call for more information at (514) 412-4400 ext. 22953 or email Murielle M. Akpa, PhD, email@example.com.